PubRank

Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients (DECENDO)

Clinical Trial ID NCT04212377

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04212377

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010 29.75
2 Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009 24.11
3 Taking dendritic cells into medicine. Nature 2007 11.82
4 Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998 7.48
5 Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999 7.28
6 BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000 6.04
7 Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010 5.23
8 Dendritic cell immunotherapy: mapping the way. Nat Med 2004 4.28
9 Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 2005 4.22
10 Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999 4.20
11 Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011 4.02
12 Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011 3.85
13 Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004 3.57
14 Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012 3.37
15 Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol 2004 3.12
16 The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003 3.06
17 Migration of dendritic cell subsets and their precursors. Annu Rev Immunol 2008 3.04
18 Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001 3.01
19 alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004 3.00
20 A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007 2.97
21 Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002 2.96
22 Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998 2.72
23 IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 2013 2.69
24 Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol 2015 2.68
25 Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005 2.56
26 Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002 2.55
27 Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010 2.51
28 Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003 2.32
29 Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One 2010 2.10
30 Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol 2004 1.85
31 Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001 1.80
32 Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999 1.66
33 How microorganisms tip the balance between interleukin-12 family members. Nat Rev Immunol 2008 1.65
34 Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003 1.57
35 A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 2001 1.49
36 Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005 1.48
37 Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 2000 1.47
38 Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 2009 1.44
39 Immunotherapy in endometrial cancer - an evolving therapeutic paradigm. Gynecol Oncol Res Pract 2015 1.42
40 Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2013 1.42
41 Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013 1.35
42 Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 2008 1.31
43 Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003 1.22
44 Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009 1.20
45 Whole tumor antigen vaccines. Semin Immunol 2010 1.19
46 Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2004 1.19
47 Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol 2009 1.16
48 CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 2013 1.12
49 Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 2007 1.12
50 Evolution of end points for cancer immunotherapy trials. Ann Oncol 2012 1.10
51 Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 2006 1.09
52 Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol 2006 1.06
53 Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 2005 1.05
54 Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res 2012 1.03
55 Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res 2010 1.03
56 Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses. Front Immunol 2014 1.01
57 Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000 1.00
58 Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. Oncoimmunology 2014 0.98
59 Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res 2013 0.96
60 Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clin Cancer Res 2015 0.96
61 Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. Anticancer Res 2013 0.96
62 Numerical and functional assessment of blood dendritic cells in prostate cancer patients. Prostate 2006 0.88
63 Human tumor-specific T lymphocytes: does function matter more than number? Curr Opin Immunol 2005 0.85
64 Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas. Int J Cancer 2002 0.85
65 Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology 2015 0.85
66 Human peripheral blood dendritic cells and monocyte subsets display similar chemokine receptor expression profiles with differential migratory responses. Scand J Immunol 2007 0.85
67 Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. Eur J Cancer 2014 0.84
68 Improving cancer immunotherapy by targeting the STATe of MDSCs. Oncoimmunology 2016 0.83
69 Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol 2008 0.79
70 Surface molecules on stimulated plasmacytoid dendritic cells are sufficient to cross-activate resting myeloid dendritic cells. Hum Immunol 2011 0.77
71 Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments. Eur J Cancer 2016 0.76
72 Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group. Gynecol Oncol 2015 0.75
73 Isolation of Human Skin Dendritic Cell Subsets. Methods Mol Biol 2016 0.75
74 Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. Gynecol Oncol 2017 0.75
75 Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin. Cancer Chemother Pharmacol 2010 0.75
Next 100